This Case is about HEALTH, INNOVATION, INTERNATIONAL BUSINESS, SOCIAL ENTERPRISE
PUBLICATION DATE: November 04, 2009 PRODUCT #: 310015-PDF-ENG
Dedicated to speeding up the growth of a safe, powerful, accessible, preventive HIV vaccine, the International AIDS Vaccine Initiative (IAVI) initiated methods of addressing the insufficient incentive arrangements that prevented advancement toward vaccines for AIDS and other diseases primarily affecting poor people in tropical nations. As an mediator nonprofit association, IAVI brought together associates from nonprofit, business, authorities and scientific research sectors with distinct viewpoints and motivations toward developing vaccines.
IAVI played several part: communicator and fair agent, integrator of knowledge regarding AIDS vaccine research, enthusiastic advocate for AIDS vaccines at national and international levels, and coordinator and supervisor of research and development initiatives.
In year 2008, IAVI invested in its own laboratories and research infrastructure, moving in clinical research and vaccine development partnerships. Should IAVI handle tensions between what’s needed to construct new incentive structures that empower key actors to work together efficiently and what’s needed to attain its mission?